Resistencia primaria a terapia antirretroviral en pacientes con infección por VIH/SIDA en Chile

Background: Resistance to antiretroviral therapy is a determining factor for therapeutic failure in HIV/AIDS. The prevalence of primary resistance (i.e. in those patients that have not received treatment) varies in different parts of the world. Aim: To study the prevalence of primary resistance to a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Afani S,Alejandro, Ayala C,Marisol, Meyer K,Andrea, Cabrera C,Roy, Acevedo M,William
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2005
Materias:	Acquired immunodeficiency syndrome Antiretroviral therapy, highly active HIV infections
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000300004
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872005000300004
record_format	dspace
spelling	oai:scielo:S0034-988720050003000042005-05-17Resistencia primaria a terapia antirretroviral en pacientes con infección por VIH/SIDA en ChileAfani S,AlejandroAyala C,MarisolMeyer K,AndreaCabrera C,RoyAcevedo M,William Acquired immunodeficiency syndrome Antiretroviral therapy, highly active HIV infections Background: Resistance to antiretroviral therapy is a determining factor for therapeutic failure in HIV/AIDS. The prevalence of primary resistance (i.e. in those patients that have not received treatment) varies in different parts of the world. Aim: To study the prevalence of primary resistance to antiretroviral drugs in patients living in Northern Santiago. Patients and methods: Viral load, lymphocyte subpopulations by flow cytometry and genotypic resistance testing were assessed in blood samples from 60 HIV-1 infected patients (mean age 37 years, 54 male). Results: Mean CD4 cell count and viral load was 200 cells/ml and 142,840 RNA copies/ml respectively. Ten mutations were identified: V179D, L10I/V, M361, L63P, A71T/V, Y115F, V118I and K20R. None of these mutations is associated to a high degree of resistance to reverse transcriptase inhibitors, nucleoside analogs (NRTI), non nucleoside analogs (NNRTI) or viral protease inhibitors. Conclusions: This is a first approach to study antiretroviral resistance in Chilean patients. This study must be amplified, since the prevalence of resistance may experience changes with time (Rev Méd Chile 2005; 133: 295-301)info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.133 n.3 20052005-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000300004es10.4067/S0034-98872005000300004
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Acquired immunodeficiency syndrome Antiretroviral therapy, highly active HIV infections
spellingShingle	Acquired immunodeficiency syndrome Antiretroviral therapy, highly active HIV infections Afani S,Alejandro Ayala C,Marisol Meyer K,Andrea Cabrera C,Roy Acevedo M,William Resistencia primaria a terapia antirretroviral en pacientes con infección por VIH/SIDA en Chile
description	Background: Resistance to antiretroviral therapy is a determining factor for therapeutic failure in HIV/AIDS. The prevalence of primary resistance (i.e. in those patients that have not received treatment) varies in different parts of the world. Aim: To study the prevalence of primary resistance to antiretroviral drugs in patients living in Northern Santiago. Patients and methods: Viral load, lymphocyte subpopulations by flow cytometry and genotypic resistance testing were assessed in blood samples from 60 HIV-1 infected patients (mean age 37 years, 54 male). Results: Mean CD4 cell count and viral load was 200 cells/ml and 142,840 RNA copies/ml respectively. Ten mutations were identified: V179D, L10I/V, M361, L63P, A71T/V, Y115F, V118I and K20R. None of these mutations is associated to a high degree of resistance to reverse transcriptase inhibitors, nucleoside analogs (NRTI), non nucleoside analogs (NNRTI) or viral protease inhibitors. Conclusions: This is a first approach to study antiretroviral resistance in Chilean patients. This study must be amplified, since the prevalence of resistance may experience changes with time (Rev Méd Chile 2005; 133: 295-301)
author	Afani S,Alejandro Ayala C,Marisol Meyer K,Andrea Cabrera C,Roy Acevedo M,William
author_facet	Afani S,Alejandro Ayala C,Marisol Meyer K,Andrea Cabrera C,Roy Acevedo M,William
author_sort	Afani S,Alejandro
title	Resistencia primaria a terapia antirretroviral en pacientes con infección por VIH/SIDA en Chile
title_short	Resistencia primaria a terapia antirretroviral en pacientes con infección por VIH/SIDA en Chile
title_full	Resistencia primaria a terapia antirretroviral en pacientes con infección por VIH/SIDA en Chile
title_fullStr	Resistencia primaria a terapia antirretroviral en pacientes con infección por VIH/SIDA en Chile
title_full_unstemmed	Resistencia primaria a terapia antirretroviral en pacientes con infección por VIH/SIDA en Chile
title_sort	resistencia primaria a terapia antirretroviral en pacientes con infección por vih/sida en chile
publisher	Sociedad Médica de Santiago
publishDate	2005
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000300004
work_keys_str_mv	AT afanisalejandro resistenciaprimariaaterapiaantirretroviralenpacientesconinfeccionporvihsidaenchile AT ayalacmarisol resistenciaprimariaaterapiaantirretroviralenpacientesconinfeccionporvihsidaenchile AT meyerkandrea resistenciaprimariaaterapiaantirretroviralenpacientesconinfeccionporvihsidaenchile AT cabreracroy resistenciaprimariaaterapiaantirretroviralenpacientesconinfeccionporvihsidaenchile AT acevedomwilliam resistenciaprimariaaterapiaantirretroviralenpacientesconinfeccionporvihsidaenchile
_version_	1718436193752842240

Resistencia primaria a terapia antirretroviral en pacientes con infección por VIH/SIDA en Chile

Ejemplares similares